ClinicalTrials.gg
TerminatedNCT00852397Updated Aug 29, 2013Results posted

A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese Patients

A Phase 2 interventional study of Apixaban and Apixaban in Acute Coronary Syndrome, sponsored by Pfizer. Terminated at 18 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-08-29.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Acute Coronary Syndrome with a site in Japan — 4 open to participants now, 7 under way, 1 of them phase 3. Acute Coronary Syndrome · Japan.

Enrollment
23rd of 25
151 · median 2,000
Started
2009
with 5 others
Phase 2
3 of 33
none open now
Registered
7th of 33
by date

Among the 33 studies in Acute Coronary Syndrome with a site in Japan, this one is the 23rd largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2009, is one of 3 in phase 2, and was the 7th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

4 of the 33 studies in Acute Coronary Syndrome with a site in Japan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Acute Coronary Syndrome with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to assess the bleeding safety (the composite endpoint of major and clinically relevant non-major bleeding) of 2 doses of apixaban (2.5 mg BID and 5.0 mg BID) or placebo in combination with standard therapy (aspirin and /or additional antiplatelet therapy) over a 24 week treatment period in selected subjects with recent (≤7 days) acute coronary syndrome.

Read the detailed description

Due to withdraw of global phase 3 study (APPRAISE-2) for safety issue, B0661004 Data monitoring committee (DMC) also recommended terminating this study. Therefore, Pfizer decided to stop this study.

03

Conditions studied

  • Acute Coronary Syndrome
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recent (≤ 7 days) ACS
  • Clinically stable, and receiving standard treatment (patients must be treated with aspirin ≤ 100 mg/day, with or without clopidogrel 75 mg/day or ticlopidine 200 mg/day) based on the physician's judgment)

Exclusion criteria

Exclusion Criteria:

  • Scheduled/planned cardiac catheterization, PCI, CABG or other invasive procedure planned in the 24 weeks (within treatment period) following randomization
  • Persistent severe hypertension, defined as systolic blood pressure of ≥180 mm Hg or diastolic pressure of ≥110 mm Hg
  • Active bleeding or at high risk for bleeding (e.g., cirrhosis of the liver, any history of intracranial hemorrhage).
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Apixaban 2.5 mg

    Drug: Apixaban

  • Experimental
    Apixaban 5.0 mg

    Drug: Apixaban

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Apixaban 2.5 mg tablet BID for 24 weeks

  • Apixaban 5.0 mg tablet BID for 24 weeks

  • OtherPlacebo

    Placebo tablet for 24 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Had Composite of International Society on Thrombosis and Haemostasis (ISTH)-Defined Major and Clinically-relevant Non-major (CRNM) Bleeding Events Occurring During the Treatment Period.

    Major bleeding event was acute clinically overt bleeding accompanied by decrease in hemoglobin of 2 g/dL or more over a 24-hour period, transfusion of 2 or more units of packed red blood cells, or bleeding that occurs in critical site (e.g., intracranial). Fatal bleeding was also major bleeding event. CRNM bleeding was acute or sub-acute clinically overt bleeding that did not satisfy the criteria for major bleeding and that led to either hospital admission for bleeding, physician guided medical or surgical treatment for bleeding or a change in antithrombotic therapy.

    Time frame: Week 0 to Week 24

Secondary outcomes

  1. Percentage of Participants Who Had One or More All Bleeding Occurring During the Treatment Period.

    All bleeding included major bleeding (including fatal bleeding), clinically-relevant non-major (CRNM) bleeding, and minor bleeding per international society on thrombosis and haemostasis (ISTH) definitions.

    Time frame: Week 0 to Week 24

  2. Percentage of Participants Who Had Major Bleeding Occurring During the Treatment Period Per International Society on Thrombosis and Haemostasis (ISTH) Definitions.

    Major bleeding event was defined as an acute clinically overt bleeding accompanied by decrease in hemoglobin of 2 g/dL or more over a 24-hour period, transfusion of 2 or more units of packed red blood cells, or bleeding that occured in critical site (e.g., intracranial). Fatal bleeding was also major bleeding event.

    Time frame: Week 0 to Week 24

  3. Percentage of Participants Who Had Thrombolysis in Myocardial Infarction (TIMI)-Defined Major Bleeding Occurring During the Treatment Period.

    TIMI major bleeding event was difined as an intracranial bleeding or clinically overt bleeding (including bleeding evident on imaging studies) associated with a \>= 5 gm/dL fall in hemoglobin or a 15% fall in hematocrit from baseline, accounting for the effect of transfusions (1 unit packed red blood cells = 1 gm/dL hemoglobin = 3% hematocrit).

    Time frame: Week 0 to Week 24

  4. Percentage of Participants Who Had Composite of All-cause Death, Non-fatal Myocardial Infarction, Unstable Angina and Stroke During 30 Days After Discontinuation of Therapy.

    Time frame: For 30 days after Week 24 or the discontinuation of study drug

  5. Percentage of Participants Who Had Composite of All-cause Death, Non-fatal Myocardial Infarction (MI), Unstable Angina, and Non-hemorrhagic Stroke Occurring During the Intended Treatment Period.

    Intended treatment period for efficacy endpoints was defined as a period starting on the day of randomization and ending at the later date of either 2-days after the last dose of study drug or Day 168/Week 24 after randomization day (or the study termination date \[19 November 2010, Japan time\]).

    Time frame: From the day of randomization to the later date of either 2-days after the last dose of study drug or Day 168/Week 24 after randomization day (or the study termination date [19 November 2010, Japan time])

Other outcomes

  1. Percentage of Participants Who Had International Society on Thrombosis and Haemostasis (ISTH)-Defined Individual Bleeding Endpoints (Clinically-relevant Non-major [CRNM] or Minor Bleeding) During the Treatment Period.

    ISTH-defined CRNM bleeding was defined as an acute or sub-acute clinically overt bleeding that did not satisfy the criteria for major bleeding and that led to either hospital admission for bleeding, physician guided medical or surgical treatment for bleeding or a change in antithrombotic therapy. ISTH defined minor bleeding event was defined as all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM bleeding were classified as minor bleeding.

    Time frame: Week 0 to Week 24

  2. Percentage of Participants Who Had Thrombolysis in Myocardial Infarction (TIMI) Defined-individual Bleeding Endpoints (Minor or Minimal Bleeding) During the Treatment Period.

    TIMI minor bleeding event was defined as a clinically overt bleeding (including bleeding evident on imaging studies) associated with a \>= 3 gm/dL fall in hemoglobin or a 9% fall in hematocrit from baseline, accounting for the effect of transfusions (1 unit packed red blood cells = 1 gm/dL hemoglobin = 3% hematocrit). TIMI minimal bleeding event was defined as a clinically overt bleeding (including bleeding evident on imaging studies) not meeting criteria for TIMI minor bleeding.

    Time frame: Week 0 to Week 24

07

Results

Posted Aug 29, 2013

Participant flow

Participant flow — Overall Study
MilestonePlaceboApixaban 2.5 mg BIDApixaban 5.0 mg BID
Started524950
Treated participants514949
Completed414136
Not completed11814
Withdrew: Adverse event464
Withdrew: Death001
Withdrew: Withdrawal by subject412
Withdrew: Study terminated by sponsor216
Withdrew: Difficulty in study site visit100
Withdrew: Protocol violation001

Outcome measures

PrimaryPercentage of Participants Who Had Composite of International Society on Thrombosis and Haemostasis (ISTH)-Defined Major and Clinically-relevant Non-major (CRNM) Bleeding Events Occurring During the Treatment Period.

Major bleeding event was acute clinically overt bleeding accompanied by decrease in hemoglobin of 2 g/dL or more over a 24-hour period, transfusion of 2 or more units of packed red blood cells, or bleeding that occurs in critical site (e.g., intracranial). Fatal bleeding was also major bleeding event. CRNM bleeding was acute or sub-acute clinically overt bleeding that did not satisfy the criteria for major bleeding and that led to either hospital admission for bleeding, physician guided medical or surgical treatment for bleeding or a change in antithrombotic therapy.

Time frame:
Week 0 to Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had Composite of International Society on Thrombosis and Haemostasis (ISTH)-Defined Major and Clinically-relevant Non-major (CRNM) Bleeding Events Occurring During the Treatment Period.
Percentage of ParticipantsPlaceboApixaban 2.5 mg BIDApixaban 5.0 mg BID
Percentage of Participants Who Had Composite of International Society on Thrombosis and Haemostasis (ISTH)-Defined Major and Clinically-relevant Non-major (CRNM) Bleeding Events Occurring During the Treatment Period.2.0 (0.10 to 9.82)4.1 (0.73 to 13.34)4.1 (0.73 to 13.34)
SecondaryPercentage of Participants Who Had One or More All Bleeding Occurring During the Treatment Period.

All bleeding included major bleeding (including fatal bleeding), clinically-relevant non-major (CRNM) bleeding, and minor bleeding per international society on thrombosis and haemostasis (ISTH) definitions.

Time frame:
Week 0 to Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had One or More All Bleeding Occurring During the Treatment Period.
Percentage of ParticipantsPlaceboApixaban 2.5 mg BIDApixaban 5.0 mg BID
Percentage of Participants Who Had One or More All Bleeding Occurring During the Treatment Period.33.3 (20.76 to 47.23)38.8 (26.01 to 53.76)44.9 (30.83 to 59.77)
SecondaryPercentage of Participants Who Had Major Bleeding Occurring During the Treatment Period Per International Society on Thrombosis and Haemostasis (ISTH) Definitions.

Major bleeding event was defined as an acute clinically overt bleeding accompanied by decrease in hemoglobin of 2 g/dL or more over a 24-hour period, transfusion of 2 or more units of packed red blood cells, or bleeding that occured in critical site (e.g., intracranial). Fatal bleeding was also major bleeding event.

Time frame:
Week 0 to Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had Major Bleeding Occurring During the Treatment Period Per International Society on Thrombosis and Haemostasis (ISTH) Definitions.
Percentage of ParticipantsPlaceboApixaban 2.5 mg BIDApixaban 5.0 mg BID
Percentage of Participants Who Had Major Bleeding Occurring During the Treatment Period Per International Society on Thrombosis and Haemostasis (ISTH) Definitions.0 (0.00 to 6.31)2.0 (0.10 to 10.24)4.1 (0.73 to 13.34)
SecondaryPercentage of Participants Who Had Thrombolysis in Myocardial Infarction (TIMI)-Defined Major Bleeding Occurring During the Treatment Period.

TIMI major bleeding event was difined as an intracranial bleeding or clinically overt bleeding (including bleeding evident on imaging studies) associated with a \>= 5 gm/dL fall in hemoglobin or a 15% fall in hematocrit from baseline, accounting for the effect of transfusions (1 unit packed red blood cells = 1 gm/dL hemoglobin = 3% hematocrit).

Time frame:
Week 0 to Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had Thrombolysis in Myocardial Infarction (TIMI)-Defined Major Bleeding Occurring During the Treatment Period.
Percentage of ParticipantsPlaceboApixaban 2.5 mg BIDApixaban 5.0 mg BID
Percentage of Participants Who Had Thrombolysis in Myocardial Infarction (TIMI)-Defined Major Bleeding Occurring During the Treatment Period.0 (0.00 to 6.31)2.0 (0.10 to 10.24)2.0 (0.10 to 10.24)
SecondaryPercentage of Participants Who Had Composite of All-cause Death, Non-fatal Myocardial Infarction, Unstable Angina and Stroke During 30 Days After Discontinuation of Therapy.
Time frame:
For 30 days after Week 24 or the discontinuation of study drug
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had Composite of All-cause Death, Non-fatal Myocardial Infarction, Unstable Angina and Stroke During 30 Days After Discontinuation of Therapy.
Percentage of ParticipantsPlaceboApixaban 2.5 mg BIDApixaban 5.0 mg BID
Percentage of Participants Who Had Composite of All-cause Death, Non-fatal Myocardial Infarction, Unstable Angina and Stroke During 30 Days After Discontinuation of Therapy.0 (0.00 to 6.31)0 (0.00 to 6.53)2 (0.10 to 10.24)
SecondaryPercentage of Participants Who Had Composite of All-cause Death, Non-fatal Myocardial Infarction (MI), Unstable Angina, and Non-hemorrhagic Stroke Occurring During the Intended Treatment Period.

Intended treatment period for efficacy endpoints was defined as a period starting on the day of randomization and ending at the later date of either 2-days after the last dose of study drug or Day 168/Week 24 after randomization day (or the study termination date \[19 November 2010, Japan time\]).

Time frame:
From the day of randomization to the later date of either 2-days after the last dose of study drug or Day 168/Week 24 after randomization day (or the study termination date [19 November 2010, Japan time])
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had Composite of All-cause Death, Non-fatal Myocardial Infarction (MI), Unstable Angina, and Non-hemorrhagic Stroke Occurring During the Intended Treatment Period.
Percentage of ParticipantsPlaceboApixaban 2.5 mg BIDApixaban 5.0 mg BID
Percentage of Participants Who Had Composite of All-cause Death, Non-fatal Myocardial Infarction (MI), Unstable Angina, and Non-hemorrhagic Stroke Occurring During the Intended Treatment Period.1.9 (0.10 to 9.63)0 (0.00 to 6.53)2.0 (0.10 to 10.03)
Other pre-specifiedPercentage of Participants Who Had International Society on Thrombosis and Haemostasis (ISTH)-Defined Individual Bleeding Endpoints (Clinically-relevant Non-major [CRNM] or Minor Bleeding) During the Treatment Period.

ISTH-defined CRNM bleeding was defined as an acute or sub-acute clinically overt bleeding that did not satisfy the criteria for major bleeding and that led to either hospital admission for bleeding, physician guided medical or surgical treatment for bleeding or a change in antithrombotic therapy. ISTH defined minor bleeding event was defined as all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM bleeding were classified as minor bleeding.

Time frame:
Week 0 to Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had International Society on Thrombosis and Haemostasis (ISTH)-Defined Individual Bleeding Endpoints (Clinically-relevant Non-major [CRNM] or Minor Bleeding) During the Treatment Period.
Percentage of ParticipantsPlaceboApixaban 2.5 mg BIDApixaban 5.0 mg BID
ISTH defined CRNM2.0 (0.10 to 9.82)2.0 (0.10 to 10.24)0 (0.00 to 6.53)
ISTH defined minor bleeding31.4 (19.63 to 45.07)36.7 (23.64 to 51.64)40.8 (27.00 to 55.79)
Other pre-specifiedPercentage of Participants Who Had Thrombolysis in Myocardial Infarction (TIMI) Defined-individual Bleeding Endpoints (Minor or Minimal Bleeding) During the Treatment Period.

TIMI minor bleeding event was defined as a clinically overt bleeding (including bleeding evident on imaging studies) associated with a \>= 3 gm/dL fall in hemoglobin or a 9% fall in hematocrit from baseline, accounting for the effect of transfusions (1 unit packed red blood cells = 1 gm/dL hemoglobin = 3% hematocrit). TIMI minimal bleeding event was defined as a clinically overt bleeding (including bleeding evident on imaging studies) not meeting criteria for TIMI minor bleeding.

Time frame:
Week 0 to Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had Thrombolysis in Myocardial Infarction (TIMI) Defined-individual Bleeding Endpoints (Minor or Minimal Bleeding) During the Treatment Period.
Percentage of ParticipantsPlaceboApixaban 2.5 mg BIDApixaban 5.0 mg BID
TIMI defined minor bleeding0 (0.00 to 6.31)2.0 (0.00 to 6.53)2.0 (0.10 to 10.24)
TIMI defined minimal bleeding33.3 (20.76 to 47.23)38.8 (26.01 to 53.76)40.8 (27.00 to 55.79)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—8/51 (15.7%)22/51 (43.1%)
Apixaban 2.5 mg BID—11/49 (22.4%)28/49 (57.1%)
Apixaban 5.0 mg BID—7/49 (14.3%)22/49 (44.9%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventPlaceboApixaban 2.5 mg BIDApixaban 5.0 mg BID
Coronary artery restenosisInjury, poisoning and procedural complications1/512/491/49
Angina pectorisCardiac disorders1/510/491/49
Angina unstableCardiac disorders1/511/491/49
Arteriospasm coronaryCardiac disorders0/510/491/49
Coronary artery occlusionCardiac disorders0/511/490/49
CataractEye disorders0/511/490/49
PterygiumEye disorders0/510/491/49
Diverticulum intestinal haemorrhagicGastrointestinal disorders0/510/491/49
Lower gastrointestinal haemorrhageGastrointestinal disorders0/511/490/49
Oesophageal ulcerGastrointestinal disorders0/510/491/49
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboApixaban 2.5 mg BIDApixaban 5.0 mg BID
NasopharyngitisInfections and infestations4/514/498/49
Post procedural haemorrhageInjury, poisoning and procedural complications6/516/494/49
Haemorrhage subcutaneousSkin and subcutaneous tissue disorders4/515/496/49
Chest discomfortGeneral disorders4/511/494/49
Blood urine presentInvestigations0/512/494/49
CoughRespiratory, thoracic and mediastinal disorders1/514/491/49
HeadacheNervous system disorders4/513/491/49
DiarrhoeaGastrointestinal disorders1/510/493/49
Gingival bleedingGastrointestinal disorders0/512/493/49
FallInjury, poisoning and procedural complications0/513/492/49

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboApixaban 2.5 mg BIDApixaban 5.0 mg BIDTotal
Mean63.9 ± 10.166.0 ± 9.064.0 ± 9.264.6 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboApixaban 2.5 mg BIDApixaban 5.0 mg BIDTotal
Female106420
Male424346131
08

Study locations

18 sites
  • Pfizer Investigational Site
    Kasuga, Fukuoka, Japan
  • Pfizer Investigational Site
    Kitakyusyu, Fukuoka, Japan
  • Pfizer Investigational Site
    Kure, Hiroshima, Japan
  • Pfizer Investigational Site
    Sapporo, Hokkaido, Japan
  • Pfizer Investigational Site
    Uji, Kyoto, Japan
  • Pfizer Investigational Site
    Ikoma, Nara, Japan
  • Pfizer Investigational Site
    Hirakata, Osaka, Japan
  • Pfizer Investigational Site
    Kawachinagano, Osaka, Japan
  • Pfizer Investigational Site
    Matsubara, Osaka, Japan
  • Pfizer Investigational Site
    Yao, Osaka, Japan
  • Pfizer Investigational Site
    Wako, Saitama, Japan
  • Pfizer Investigational Site
    Sunto, Shizuoka, Japan
  • Pfizer Investigational Site
    Minato-Ku, Tokyo, Japan
  • Pfizer Investigational Site
    Shinagawa, Tokyo, Japan
  • Pfizer Investigational Site
    Gifu, Japan
  • Pfizer Investigational Site
    Hiroshima, Japan
  • Pfizer Investigational Site
    Kumamoto, Japan
  • Pfizer Investigational Site
    Osaka, Japan
09

References and documents

Publications

  • Ogawa H, Goto S, Matsuzaki M, Hiro S, Shima D; APPRAISE-J investigators. Randomized, double-blind trial to evaluate the safety of apixaban with antiplatelet therapy after acute coronary syndrome in Japanese patients (APPRAISE-J). Circ J. 2013;77(9):2341-8. doi: 10.1253/circj.cj-13-0209. Epub 2013 Jun 7. PubMed 23748920 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2009
First posted
Feb 27, 2009
Start
Apr 2009
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Aug 29, 2013
Last update
Aug 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00852397
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 27, 2009
Start date
Apr 2009
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Aug 29, 2013
Last update
Aug 29, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion